This study represents a good example od lead pharmacokinetic optimization. Combined application of analytical techniques, SAR analysis, chemical synthesis and binding studies enabled the identification of compound UCM924 (N-{2-[(3-bromophenyl)-(4-fluorophenyl)amino]ethyl}acetamide) as an alternative to the hypno-inducing lead compound UCM765, an MT2 melatonin receptor partial agonist, which exhibits a very short half-life in the presence of rat oxidative enzymes. The new analogue UCM924 displayed a binding profile similar to that of the parent UCM765 on cloned human melatonin receptors and a significantly longer half-life in the presence of rat liver S9 fraction.

N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands.

SPADONI, GILBERTO;BEDINI, ANNALIDA;LUCARINI, SIMONE;TARZIA, GIORGIO
2009-01-01

Abstract

This study represents a good example od lead pharmacokinetic optimization. Combined application of analytical techniques, SAR analysis, chemical synthesis and binding studies enabled the identification of compound UCM924 (N-{2-[(3-bromophenyl)-(4-fluorophenyl)amino]ethyl}acetamide) as an alternative to the hypno-inducing lead compound UCM765, an MT2 melatonin receptor partial agonist, which exhibits a very short half-life in the presence of rat oxidative enzymes. The new analogue UCM924 displayed a binding profile similar to that of the parent UCM765 on cloned human melatonin receptors and a significantly longer half-life in the presence of rat liver S9 fraction.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11576/2504142
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 28
social impact